The China M-protein Screening Project in First-degree Relatives of Myeloma Patient - The CHAPERONE Study

Recruiting now

Conditions studied: Multiple Myeloma, Monoclonal Gammopathy of Undetermined Significance

In brief

The goal of the China Monoclonal Gammopathy Screening Project in First-degree Relatives of Patients With Multiple Myeloma (CHAPERONE) study is to assess the clinical significance of screening for monoclonal gammopathy (M-protein) in first-degree relatives of patients with multiple myeloma in China population, and establish a prospective cohort of individuals with monoclonal gammopathy of undetermined significance (MGUS), a precursor conditions to multiple myeloma. We will study these patients as a means to identify risk factors for progression to symptomatic multiple myeloma.

Key facts

Study ID

NCT05965115

Run by

Shanghai Zhongshan Hospital

People needed

10000

Starts

2023-07-01

Expected to finish

2035-08-01

Last updated by the study team

2023-08-01

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Male or female over the age of 18;
• First-degree relatives (including parents, children, and biological siblings) have multiple myeloma diagnosed by the International Myeloma Working Group (IMWG) Myeloma Diagnostic Criteria;
• Understand the purpose and procedure of this trial and voluntarily participate in this screening study;
• Participants should be willing and able to follow the study follow-up plan and other protocol requirements.

You may not qualify if…

• Patients with a known diagnosis of plasma cell diseases, such as MGUS, smoldering myeloma (SMM), or multiple myeloma

Where it is running

• Zhongshan Hospital，Fudan University — Shanghai, Shanghai Municipality, China (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.